Abstract

CORDERO, Byron Enrique Peña  and  ESPINOZA, Esteban Adrián Reibán. Thrombopoietin agonists as pharmacological management of primary immune thrombocytopenia. Vive Rev. Salud [online]. 2023, vol.6, n.17, pp.647-662.  Epub May 08, 2023. ISSN 2664-3243.  https://doi.org/10.33996/revistavive.v6i17.253.

Primary immune thrombocytopenia (PIT) is an autoimmune hematological disease that is distinguished by having platelets in a number lower than 100,000, which causes in patients clinical manifestations such as the presence of ecchymosis, petechiae to massive hemorrhages that can compromise the patient's life. For its diagnosis, complementary tests are performed, since it is a pathology in which there is no standard or specific test to diagnose it, and its treatment, whether first, second or third line, will depend on the number of platelets and the stage of the disease, with thrombopoietin agonists standing out. Objective. To describe the pharmacological management of Primary Immune Thrombocytopenia (PIT) through the administration of thrombopoietin agonists. Methodology. A systematic review was performed using PRISMA methodology, the information collected was done in scientific databases such as Pubmed, Science Direct, including articles published within the last 5 years, in English and Spanish, related to the use of thrombopoietin agonists and primary immune thrombocytopenia. Results. Initially 102 were selected in PubMed and ScienceDirect, after the verification processes, 18 articles remained for data extraction and analysis. Conclusion. Thrombopoietin agonists are safe drugs, but the risk-benefit should always be assessed before using them in patients with PIT, because each patient is unique and their response to treatment may vary. However, they should be used with caution in patients with a history of thromboembolic disease or who are at high risk of developing it.

Keywords : Therapeutics; Thrombopoietin; Blood Platelets.

        · abstract in Spanish | Portuguese     · text in Spanish     · Spanish ( pdf )